X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GNbAC1 (temelimab) is an W-ENV neutralizer antibody drug canditate, developed by GeNeuro, administered via intravenous infusion for the treatment of Post-COVID 19.
Lead Product(s): Temelimab
Therapeutic Area: Infections and Infectious Diseases Product Name: GNbAC1
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
The trial will evaluate GNbAC1 (temelimab), the antiW-ENV antibody developed by GeNeuro, as a Disease Modifying Therapy in long-COVID patients suffering from concentration or fatigue problems.
Lead Product(s): Temelimab
Therapeutic Area: Infections and Infectious Diseases Product Name: GNbAC1
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2022
Details:
Government funding will support a Phase 2 clinical trial with temelimab in patients suffering from Long- COVID with neurological and psychiatric symptoms.
Lead Product(s): Temelimab
Therapeutic Area: Infections and Infectious Diseases Product Name: GNbAC1
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Swiss Federal Office of Public Health
Deal Size: $7.3 million Upfront Cash: Undisclosed
Deal Type: Funding December 13, 2021
Details:
Research aims to confirm evidence of the expression of human endogenous retrovirus W envelope protein (HERV-W ENV or W-ENV) in long-haul COVID patients, and identify affected patients who may benefit from a treatment with GeNeuro’s temelimab.
Lead Product(s): Temelimab
Therapeutic Area: Infections and Infectious Diseases Product Name: GNbAC1
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Northwestern University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 24, 2021
Details:
Successfully completing this private placement provides GeNeuro the means to complete the planned study of temelimab in multiple sclerosis patients with disability progression without relapses.
Lead Product(s): Temelimab
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bryan, Garnier & Co
Deal Size: $19.3 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 31, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
